CEO of Biontech SE Ugur Sahin has expressed confidence that the Corona-vaccine in development by the biotechnology company could be available by the end of the year.
The vaccine could quickly be approved, if the ongoing clinical studies of Biontech and its US based partner Pfizer confirm the positive data received so far, Sahin said on Thursday. He is expecting more results within two weeks.
Last October, Uğur Şahin traveled from Germany to New York to launch the initial public offering of his decade-old biotechnology company with a message about its new and unproven technology. “We rely on the patient’s immune system,” Şahin said before ringing the opening bell at Nasdaq’s market site. “We want to activate the patient’s immune cells to identify, to detect, and eliminate tumor cells.”